Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on Maintenance Treatment
| Autor: | Ann-Charlotte Wikström, Per Marits, Helena Rolandsdotter, Ulf Sundin, Michael Eberhardson, Yigael Finkel, Ulrika L. Fagerberg |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Male
Crohn’s disease Inflammatory bowel disease Gastroenterology trough levels lcsh:Chemistry 0302 clinical medicine antibodies toward infliximab Medicine Child lcsh:QH301-705.5 Spectroscopy medicine.diagnostic_test biology Anti-Inflammatory Agents Non-Steroidal General Medicine Computer Science Applications Treatment Outcome Child Preschool 030220 oncology & carcinogenesis Erythrocyte sedimentation rate Cohort Female 030211 gastroenterology & hepatology Drug Monitoring Antibody medicine.drug medicine.medical_specialty Adolescent Trough (economics) Article Catalysis Inorganic Chemistry 03 medical and health sciences inflammatory bowel disease Internal medicine Humans Physical and Theoretical Chemistry Molecular Biology ulcerative colitis business.industry Organic Chemistry Albumin Infant Inflammatory Bowel Diseases medicine.disease Infliximab lcsh:Biology (General) lcsh:QD1-999 Immunology biology.protein Trough level business |
| Zdroj: | International Journal of Molecular Sciences, Vol 18, Iss 3, p 575 (2017) International Journal of Molecular Sciences; Volume 18; Issue 3; Pages: 575 International Journal of Molecular Sciences |
| ISSN: | 1422-0067 |
| Popis: | The role of trough serum infliximab (s-IFX) and antibodies toward IFX (ATI) during maintenance treatment remains unclear in children. The aim of the present study was to investigate trough s-IFX and ATI to identify any correlation with inflammatory activity and clinical response in a pediatric inflammatory bowel disease (IBD) cohort. We investigated the s-IFX trough levels in pediatric IBD patients (n = 45) on maintenance IFX treatment. Ninety-three blood samples were collected and demographics, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and albumin were recorded. The mean s-IFX trough level was 5.2 µg/mL. The mean trough s-IFX level was significantly higher in the samples taken during remission (7.2 µg/mL) compared to active disease (4.5 µg/mL, p < 0.05). The trough s-IFX levels correlated with ESR, CRP, and albumin. S-IFX was undetectable in eight of the patients, all with positive ATI and active disease. Surprisingly, clinical and biochemical remission was observed at only 26 of the 93 visits. The correlation between dose variations and changes in trough s-IFX was not evident. In line with studies in adults, the s-IFX trough levels correlated with response to infliximab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|